MOYOM Advances European Regenerative Aesthetics Through APHRANEL® EU MDR Certification and Strategic Scientific Collaboration with Expert2Expert
LONDON, July 31, 2026 /PRNewswire/ -- MOYOM, the biotechnology company behind APHRANEL®, today announced two major milestones in its European strategy: the achievement of European Medical Device Regulation (EU MDR) certification for APHRANEL® and the establishment of a strategic...
LONDON, July 31, 2026 /PRNewswire/ -- MOYOM, the biotechnology company behind APHRANEL®, today announced two major milestones in its European strategy: the achievement of European Medical Device Regulation (EU MDR) certification for APHRANEL® and the establishment of a strategic...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.